Subtypes of Breast Cancer in Lao P.D.R.: A Study in a Limited-Resource Setting
- PMID: 30806064
- PMCID: PMC6897003
- DOI: 10.31557/APJCP.2019.20.2.589
Subtypes of Breast Cancer in Lao P.D.R.: A Study in a Limited-Resource Setting
Abstract
Aim: The purpose of this study is to evaluate the prevalence of the immunohistochemical subtypes of breast cancer among Lao women by using immunohistochemistry (according to the St. Gallen 2017 guidelines) and to study their correlation to clinicopathological features in order to help guide better treatment plans for patients. Materials and methods: Formalin-fixed and paraffin embedded tissue blocks of 76 cases of primary invasive breast cancer were retrieved from the University of Health Sciences, Vientiane, Lao PDR, from 2013 to 2016. Patients’ information and previous histological reports were reviewed. Immunohistochemistry was done using antibodies against estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2/neu) and Ki-67 (MIB-1). Results: The mean age of the patients was 49 years, and the major histologic type was invasive ductal carcinoma, NOS (90.7%). The proportion of each subtype was hormone receptor-positive and HER2-negative, 44.7%; hormone receptor-positive and HER2-positive, 3.9%; hormone receptor-negative and HER2-positive, 13.2%; and triple-negative, 38.2%. ER was positive in 40.8% of the cases, while PR was positive in 47.4%. More than half of the cases were poorly differentiated cancer (65.8%), followed by moderately differentiated (34.2%). Tumors presented with pT2 (60.5%), followed by pT3 (25.0%) and pT4 (7.9%). Conclusion: Breast cancer among Lao women is characterized by a large percentage of the triple-negative subtype that is less susceptible to hormonal treatments. The empirical treatment with tamoxifen should be reconsidered since it would be less effective to these patients. More importantly, basic pathology services should be the first requirement in Lao PDR in order to provide adequate care.
Keywords: Breast cancer; low-resources countries; immunohistochemistry; histological type; estrogen receptor.
Creative Commons Attribution License
Conflict of interest statement
The authors declare no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Figures

Similar articles
-
Breast Cancer Molecular Subtypes Defined by ER/PR and HER2 Status: Association with Clinicopathologic Parameters in Ivorian Patients.Asian Pac J Cancer Prev. 2016;17(4):1973-8. doi: 10.7314/apjcp.2016.17.4.1973. Asian Pac J Cancer Prev. 2016. PMID: 27221883
-
Distribution of molecular breast cancer subtypes among Algerian women and correlation with clinical and tumor characteristics: a population-based study.Breast Dis. 2015;35(2):95-102. doi: 10.3233/BD-150398. Breast Dis. 2015. PMID: 25736840
-
Immunohistochemical Evaluation of Ki-67 and Comparison with Clinicopathologic Factors in Breast Carcinomas.Asian Pac J Cancer Prev. 2019 Jan 25;20(1):73-79. doi: 10.31557/APJCP.2019.20.1.73. Asian Pac J Cancer Prev. 2019. PMID: 30678383 Free PMC article.
-
Impact of molecular subtypes classification concordance between preoperative core needle biopsy and surgical specimen on early breast cancer management: Single-institution experience and review of published literature.Eur J Surg Oncol. 2017 Apr;43(4):642-648. doi: 10.1016/j.ejso.2016.10.025. Epub 2016 Nov 17. Eur J Surg Oncol. 2017. PMID: 27889196 Review.
-
Overview of breast cancer.JAAPA. 2019 Oct;32(10):13-17. doi: 10.1097/01.JAA.0000580524.95733.3d. JAAPA. 2019. PMID: 31513033 Review.
Cited by
-
Intercontinental Comparison of Immunohistochemical Subtypes Among Individuals With Breast Cancer in South-East Asia and South America: A Scoping Systematic Review and Meta-Analysis of Observational Studies.World J Oncol. 2024 Jun;15(3):355-371. doi: 10.14740/wjon1788. Epub 2024 May 7. World J Oncol. 2024. PMID: 38751698 Free PMC article.
-
Breast Cancer in Asia: Incidence, Mortality, Early Detection, Mammography Programs, and Risk-Based Screening Initiatives.Cancers (Basel). 2022 Aug 30;14(17):4218. doi: 10.3390/cancers14174218. Cancers (Basel). 2022. PMID: 36077752 Free PMC article. Review.
References
-
- Adebamowo CA, Famooto A, Ogundiran TO, et al. Immunohistochemical and molecular subtypes of breast cancer in Nigeria. Breast Cancer Res Treat. 2008;110:183–8. - PubMed
-
- Andre F, Arnedos M, Goubar A, et al. Ki67-no evidence for its use in node-positive breast cancer. Nat Rev Clin Oncol. 2015;12:296–301. - PubMed
-
- Bird PA, Hill AG, Houssami N. Poor hormone receptor expression in East African breast cancer: evidence of a biologically different disease? Ann Surg Oncol. 2008;15:1983–8. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous